Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $95.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price hoisted by HC Wainwright from $82.00 to $95.00 in a report published on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q4 2024 earnings at ($1.37) EPS, FY2024 earnings at ($6.26) EPS, Q1 2025 earnings at ($1.20) EPS, Q2 2025 earnings at ($1.11) EPS, Q3 2025 earnings at ($1.03) EPS, Q4 2025 earnings at ($0.96) EPS, FY2025 earnings at ($4.29) EPS, FY2026 earnings at ($1.18) EPS, FY2027 earnings at $3.46 EPS and FY2028 earnings at $9.33 EPS.

Other equities research analysts have also issued research reports about the company. TD Cowen increased their price target on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Wedbush boosted their target price on shares of Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. Royal Bank of Canada reissued an “outperform” rating and set a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Thursday, September 26th. Wells Fargo & Company lifted their price target on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Finally, Barclays decreased their price objective on Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $86.69.

Ultragenyx Pharmaceutical Price Performance

Ultragenyx Pharmaceutical stock traded down $0.07 during mid-day trading on Wednesday, reaching $50.36. 1,246,799 shares of the stock traded hands, compared to its average volume of 783,398. Ultragenyx Pharmaceutical has a 12-month low of $34.06 and a 12-month high of $60.37. The business’s 50-day moving average is $55.06 and its 200-day moving average is $48.17. The stock has a market capitalization of $4.64 billion, a PE ratio of -7.78 and a beta of 0.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.45) by $0.05. The firm had revenue of $139.49 million during the quarter, compared to analyst estimates of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 197.73%. The business’s revenue for the quarter was up 42.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($2.23) EPS. Equities analysts anticipate that Ultragenyx Pharmaceutical will post -6.29 EPS for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 7,465 shares of the stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at approximately $4,869,800.76. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,465 shares of the company’s stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the sale, the chief financial officer now owns 92,301 shares of the company’s stock, valued at approximately $4,869,800.76. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Emil D. Kakkis sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the transaction, the chief executive officer now owns 2,223,985 shares of the company’s stock, valued at $124,209,562.25. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,556 shares of company stock worth $1,515,967. Company insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors have recently bought and sold shares of RARE. Vanguard Group Inc. grew its stake in Ultragenyx Pharmaceutical by 0.3% during the first quarter. Vanguard Group Inc. now owns 8,700,007 shares of the biopharmaceutical company’s stock worth $406,203,000 after buying an additional 26,575 shares during the period. Price T Rowe Associates Inc. MD raised its position in Ultragenyx Pharmaceutical by 3.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,568,873 shares of the biopharmaceutical company’s stock valued at $166,632,000 after purchasing an additional 120,175 shares during the period. Clearbridge Investments LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 0.7% during the first quarter. Clearbridge Investments LLC now owns 2,400,854 shares of the biopharmaceutical company’s stock worth $112,096,000 after purchasing an additional 17,362 shares in the last quarter. Federated Hermes Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 8.7% in the second quarter. Federated Hermes Inc. now owns 2,107,025 shares of the biopharmaceutical company’s stock worth $86,599,000 after buying an additional 168,345 shares during the period. Finally, Millennium Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 103.8% in the second quarter. Millennium Management LLC now owns 1,850,734 shares of the biopharmaceutical company’s stock valued at $76,065,000 after buying an additional 942,529 shares in the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.